Drugs / XmAb18968
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05038644 | Feb 2022 → Apr 2024 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma, acute myeloid leukemia | Ehab L Atallah | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb18968 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05038644 ↗ |
| Route | Intravenous | “0.1 mg intravenous (IV) Cycle (C) 1 Day (D) 1” NCT05038644 ↗ |